Zacks Investment Research on MSN2d
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in ...
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...
Scientists have finally pinned down a protein that’s largely responsible for Parkinson’s disease. Known as PINK1, the protein ...
Dogs impacted by chronic kidney disease (CKD) can live more manageable lives thanks to a new study from experts at the Koret ...
The study, published in the Journal of Veterinary Internal Medicine, examined the effects of paricalcitol -- a synthetic form ...
A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered—which ...
A new study led by Dr. Hilla Chen, Prof. Gilad Segev and Dr. Michal Mazaki-Tovi from the Koret School of Veterinary Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results